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Protozoa of the genus Leishmania cause a wide variety of pathologies ranging from self-healing skin lesions to visceral damage,
depending on the parasite species. The outcome of infection depends on the quality of the adaptive immune response, which is
determined by parasite factors and the host genetic background. Innate responses, resulting in the generation of mediators with
anti-leishmanial activity, contribute to parasite control and help the development of eﬃcient adaptive responses. Among those,
the potential contribution of members of the Toll-like receptors (TLRs) family in the control of Leishmania infections started to be
investigated about a decade ago. Although most studies appoint a protective role for TLRs, there is growing evidence that in some
cases, TLRs facilitate infection. This review highlights recent advances in TLR function during Leishmania infections and discusses
their potential role in restraining parasite growth versus yielding disease.
1.Introduction
Infections with parasitic protozoa have been a long-term
health issue in the tropical and subtropical regions of the
globe. Among those, diseases caused by infections with
microbes of the Leishmania genus are one of the most wide-
spread inﬁrmities. Leishmania parasites are transmitted to
the vertebrate host by the sand ﬂy bite that injects the
infective metacyclic forms under the skin. The ﬂagellated
parasites are rapidly engulfed by phagocytic cells either
resident or recruited to the wound site (i.e., neutrophils,
macrophages and dendritic cells), reviewed in [1]. While
the passage through neutrophils is believed to be transient,
serving as a temporary safe hideaway, the parasites are able
to establish productive infections in macrophages, where
they diﬀerentiate to amastigotes and replicate inside the
parasitophorous vacuole. The pathology resulting from the
infection is related to the parasite species that can either
induce cutaneous (i.e., L. major, L .m e x i c a n a ,L .g u y a n e n s i s ),
mucocutaneous (i.e., L. amazonensis, L. braziliensis), or vis-
ceralleishmaniasis(L.donovani,L.chagasi).Theoutcomesof
infections are complex, depending not only on the parasite
species but also on the immune status of the host. As an
example, although L. amazonensis is primarily associated
with cutaneous manifestations, it can also provoke muco-
cutaneous and/or diﬀuse cutaneous leishmaniasis. Infections
with L. panamensis or L. braziliensis can generate a persistent
hyperinﬂammatory response, where a mixed T-helper 1
(Th1)/T-helper 2 (Th2) response is observed, leading to
nonresolving lesions in humans [2, 3]. L. guyanensis can also
migrate away from the primary infection site, generating
distal secondary lesions similar to those observed with L.
braziliensis [4].
Cutaneous leishmaniasis comprises self-healing skin
ulcers in immunocompetent individuals, however, para-
site persistence remains, helping to maintain protective
immunity [5]. Mucocutaneous leishmaniasis involves par-
asitic dissemination to the nasopharyngeal area, leading
to destructive secondary lesions. It is characterized by a
persistent inﬂammatory response associated with increased
expression of proinﬂammatory mediators that are crucial for
the recruitment of cells to the site of infection [6]. About 5 to
10%ofindividualsasymptomaticorwithresolvedcutaneous
lesions may develop mucocutaneous lesions [7, 8]. Although
the development of a type-1 immune response is crucial for2 Journal of Parasitology Research
the control of parasites, unresolved inﬂammation can derive
from lack of an appropriate modulation of those responses
in the case of tegumentary leishmaniasis (reviewed in [9]).
On the other hand, the progression of visceral leishmaniasis
is often accompanied by a decay in the type-1 response [10].
In this scenario, increasing immunosuppression contributes
to disease progression not only due to the presence of
immunoregulatory cytokines but also because of partial
destruction of lymphoid tissues [11, 12].
The mouse model for cutaneous leishmaniasis caused by
L. major has been largely explored over the years, providing
a solid body of data deﬁning the immunological mecha-
nisms involved in mounting innate and adaptive protective
responses(reviewedin[13]).However,thoseﬁndingscannot
be readily extrapolated for models of infections by other
Leishmania species, rendering it indispensable to investigate
the parameters of immunological responses for each com-
bination of parasite species, host cell, and/or animal model
for the disease. Although adaptive immunity is essential for
the resolution of infection, there is growing evidence that
innate mechanisms make an important contribution to the
antiparasitic defenses.
Innate responses develop after the initial sensing of
invading microbes, leading to the production of eﬀector
molecules that contribute to contain initial infection and to
mount the subsequent adaptive immune response [14]. The
early immune reaction against L. major, L. braziliensis, and L.
infantum during experimental infections has been analyzed
in detail, revealing, for example, diﬀerential susceptibility
to nitric oxide (NO) and reactive oxygen species (ROS) in
phagocytes located at distinct organs. While the production
of NO is required for the leishmanicidal activity against L.
major [15]a n dL. braziliensis [16] in the skin of infected
mice, it is dispensable in the spleen and mildly important in
the lymph node. Although NO was believed to be important
to the control of L. donovani in the liver and spleen of mice
[17], it was later established that neither iNOS nor NADPH
oxidase (phox) is essential to restrict parasite replication in
the liver [18, 19]. The relative importance of such mediators
has been recently covered by Liese and coworkers [14]a n d
will not be explored in this review.
The potential contribution of Toll-like receptors in
ﬁghting parasitic infections has gained attention in the
last decade. We will cover the main ﬁndings regarding the
interplay between Toll-mediated responses and Leishmania
infections.
2.Toll-Like Receptors (TLRs) andLeishmania
Toll-like receptors (TLRs) are hallmarks of cellular receptors
that recognize pathogen-associated molecules and partici-
pate in innate responses to infections (reviewed in [10]).
There are currently 13 mammalian TLRs described, while
TLRs 1–9 are functionally conserved between humans and
mice, TLR10 seems to be functional in humans but divergent
at the C-terminus in the mouse, rendering it inoperant.
TLR11 is functional in the mouse but truncated in humans.
The conserved TLRs can be divided into extracellular:
TLR1-2, TLR4-6, and TLR11 [20] or intracellular: TLR3,
TLR7-9 and TLR13 [21], and those receptors recognize spe-
ciﬁcgroupsofligandseitheratthecellsurfaceorintheendo-
somal compartment, respectively [22]. Each TLR detects
distinct sets of molecules from viruses, bacteria, fungi, and
parasites, and upon binding, they recruit diﬀerent adaptor
proteins such as MyD88 or TRIF [22]. TLRs initiate innate
responses in a variety of ways, leading to the production
of inﬂammatory cytokines by macrophages and diﬀerent
subtypes of dendritic cells (DCs) and of type I interferons
(IFN) by inﬂammatory monocytes, macrophages, and DCs
[22]. Neutrophils also express the majority of TLR family
members and several coreceptors but lack intracellular TLR3
and TLR7 (reviewed in [23]). In those cells, TLR activation
often leads to the generation of reactive oxygen species
(ROS), cytokine production, increased cellular survival,
receptor expression, and phagocytosis [24].
The microbial molecules recognized by TLRs are
conserved polymers, such as bacterial lipopolysaccharides
(LPSs), peptidoglycans, unmethylated bacterial DNA, and
double-strand viral RNA, among others. Since protozoans
lack most of these structures, TLRs must recognize other
groups of molecules in order to sense those microbes.
The recognition of Trypanosoma cruzi tGPI (glicosylphos-
phatidylinositol anchor) by TLR2 [35] and of glycoinosi-
tolphospholipids by TLR4 [25], of Plasmodium hemozoin by
TLR9 [26], and of the proﬁlin-like molecule of Toxoplasma
gondii by TLR11 [30]a r es u c he x a m p l e s .
The phagocytosis of Leishmania by macrophages, con-
trary to the observed with other pathogens, is marked
by the absence of many proinﬂammatory cytokines [27].
Furthermore, infected macrophages become unresponsive
to subsequent challenges with the TLR4 ligand LPS, a
feature that is associated with parasite phosphoglycans [28,
36]. Since TLR recognition is often associated with the
production of proinﬂammatory cytokines and with the gen-
eration of additional eﬀector molecules, it is unquestionably
important to determine the implications of TLR activation
during Leishmania infections. A few Leishmania-derived
molecules have been reported to activate TLRs, and the
majority of the studies to date focused on the activation of
TLR2, TLR4, and TLR9.
2.1. TLR2 and MyD88. Initial experiments suggesting that
Leishmania induces TLR-mediated responses came from
studies using cells lacking the adaptor molecule MyD88 [29].
Those analyses showed that L. major activates the promoter
region of IL-1α, but not of IL-6, IL-8, or IL-10, through
MyD88-dependent pathway in macrophages [29]. It was
then reported that MyD88-dependent pathways are required
for the development of the protective IL-12-mediated Th1
response against the L. major in C57BL6 resistant mice,
since MyD88−/−mice infected with L. major developed a
nonprotective Th2 response [37]. The animals had enlarged
nonhealing lesions and low IL-12 plasma levels suggesting
that TLR-mediated responses were important to develop
eﬀective antiparasite immunity. At the same time, it was
revealed that the higher susceptibility of MyD88−/− mice toJournal of Parasitology Research 3
L. major i n f e c t i o n sc o r r e l a t e dw i t he l e v a t e dl e v e l so fI L - 4 ,
despite the lack of ulcerating lesions [38]. L. donovani, L.
braziliensis, L. major, and L. mexicana induce the maturation
of DCs in vivo and the observation that DC maturation
was attenuated in MyD88−/− mice infected with L. donovani
implied the involvement of TLRs in DC maturation and
T-cell priming [39]. Although the studies using MyD88-
deﬁcient mice suggested that TLRs inﬂuence the adaptive
immuneresponseduringLeishmaniainfections,theydidnot
oﬀer undisputable evidence for the participation of TLRs,
mainly because MyD88 can also function as an adaptor
protein to the IL-1 receptor [40]. Furthermore, there are
pathways downstream of TLR3 and TLR4 which are inde-
pendent of MyD88, such as the activation of TLR4 through
IRF3 leading to the production of type-1 interferons [41].
Therefore, it became crucial to prove the direct involvement
of TLRs for the responses observed in the infection models
described above.
ThedirectactivationofTLR2byLeishmaniacomponents
was subsequently reported. Puriﬁed L. major lipophospho-
glycan (LPG) induced the upregulation and stimulation of
TLR2 on human NK cells, with additional enhancement of
TNF-α and IFN-γ [42]. LPGs of L. major, L. mexicana, L.
aethiopica,a n dL. tropica were deﬁned as TLR2 ligands in
studies using murine macrophages, although the stimulation
with L. tropica LPG was only marginal [34]. At this point,
the possibility that species- or strain-speciﬁc structural
diﬀerences in the phosphoglycan chain could contribute
to receptor recognition or activation was raised. Those
studies revealed that the induction of TNF-α synthesis by
L. major LPG required the presence of the lipid anchor and
of functional MyD88. Intriguingly, LPG also induced the
expression of suppressors of the cytokine signaling family
proteins SOCS-1 and SOCS-3 [34]. The ﬁnding that negative
modulators of cytokine synthesis were also induced by LPG
indicated that TLR2 stimulation by L. major can lead to
both positive and negative inﬂammatory signals. The fact
that SOCS1 itself directly downmodulates TLR4 signaling
pathways [43] illustrates how the initial stimulation of TLR2
by L. major can ultimately lead to the attenuation of further
TLR responses.
Morerecently,itwasshown thatLPGstimulates cytokine
production by human peripheral blood mononuclear cells
via TLR2 as well [31]. Although cellular LPG isolated from
promastigotes is structurally similar to soluble LPG present
in culture supernatants, they diﬀer in the average number
of phosphorylated oligosaccharide repeat units and in glycan
composition [32]. In the above-mentioned study, while both
forms of LPG induced the production of ROS in a TLR-2-
dependent manner, Th1-promoting cytokines were induced
solely by soluble LPG, leading to the proposal that the
ﬁrst encounter and recognition of L. major by membrane-
derived LPG after interaction with TLR2 provides a cytokine
milieu for consequent Th2 diﬀerentiation [31]. Later on, the
same authors provided evidence that the induction of NO
production by macrophage cell lines was achieved with both
LPG forms, and was dependent on TLR2, but not on TLR4
signaling [44]. More recently, synthetic oligosaccharides
based on the LPG structure were shown to induce IL-12
and Th1 responses in vivo through TLR2, corroborating
that TLR2 stimulation by Leishmania LPG potentiates the
inﬂammatory responses in mice [33]. Those ﬁndings assign
a protective role for TLR2 and MyD88 during L. major
infection, in particular, TLR2 seems required to mount an
eﬀective Th1 response (Figure 1, left pannel).
The consequences of TLR2 activation to the control of
leishmaniasis was further veriﬁed using the TLR2 ligand,
arabinosylated lipoarabinomannan (Ara-LAM), in a Balb/c
model of visceral leishmaniasis [45]. Ara-LAM induced
the expression of TLR2 in macrophages infected with L.
donovani in vitro, which was accompanied by the production
of NO and of proinﬂammatory cytokines. Mice pre-treated
withAra-LAMandsubsequentlychallengedwithL.donovani
showed around 80% reduction of infection in the liver and
thespleen,paralleledbyastrongTh1response.However,one
should take care at interpreting those results since Ara-LAM
could exert its eﬀect in vivo through additional mechanisms
besides TLR2 activation.
The parasite can also modulate the expression of TLRs,
interfering with their availability and/or the subsequent
quality of the responses mediated by those receptors. For
example, two antigens isolated from L. donovani amastigotes
were shown to upregulate TLR2 expression in RAW264
macrophages [49]. The 65 and 98kDa proteins induced
elevated levels of MAPK p38, as well as its phosphorylation
in relation to that of ERK1/2, leading the authors to
conclude that they induced the activation of TLR signaling
proteins. However, one should interpret those conclusions
with caution, speciﬁc controls for the activation of TLR2
(i.e., neutralizing antibodies or cells derived from knock-
out mice) were lacking in this study. Furthermore, the
contribution of minor nonproteinaceous contaminants in
the preparations cannot be excluded considering that the
antigens were isolated by elution from SDS-PAGE gels and
were not further puriﬁed. In another study, while verifying
the expression of TLRs during the infection of Balb/c mice
withL.chagasi,attemptsweremadetocorrelateupregulation
of TLR expression with a potential role for those recep-
tors in generating inﬂammatory versus anti-inﬂammatory
responses [50]. The authors observed upregulation of TLR2
and TLR4 from day 1 to day 28 postinfection, and increased
expression correlated with higher mRNA levels for TNFα,
IL-17, IL-10, and TGFβ during early infection. On the
other hand, there was an inverse correlation between the
expression of TLR2-4 and that of IL-12 or IFN-γ,a n d
parasite load, leading to the proposal that those TLRs
are involved in the recognition of the parasite during
visceral leishmaniasis. However, while most of those studies
evaluated the induction of cytokine mRNA and of mRNA
for TLRs, they did not provide direct evidence that TLRs are
required for the induction of cytokine synthesis. Increased
expression of TLRs might have occurred as a consequence
of the inﬂammatory environment in the spleen, making it
diﬃcult to evaluate to what extent the activation of TLRs is
implicated in those ﬁndings.
L.panamensiswasfoundtoinduceupregulationofTLR1,
TLR2, TLR3, and TLR4 in human primary macrophages
[51]. The activities of TLR4 and TLR3 correlated with4 Journal of Parasitology Research
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Figure 1: Model for the activation of TLR2 by Leishmania sp., leading to a proinﬂammatory (left), or anti-inﬂammatory arm (centre and
right). In early studies, L. major stimulated the transcription of IL1α through a MyD88-dependent pathway, but not the IL1α production
at the protein level, suggesting the triggering of anti-inﬂammatory stimuli negatively controlling IL1-α production [22]. LPG or additional
undeﬁned TLR2 ligands promote the synthesis of cytokines, nitric oxide (NO), and reactive oxygen species (ROS) that are related to parasite
killing and to the development of a protective Th1 response, through MyD-88-dependent pathways [22–29]. L. major LPG also induces the
productionofsuppressorsofthecytokinesignalingfamilyproteinsSOCS-1andSOCS-3[26],whoseactivitiesareassociatedwithdiminished
cytokine production and prevention of TLR4 signaling [30]. Lack of TLR2 increased the resistance to infections with L. braziliensis [31]
and L. amazonensis [32] decreased lesion formation and parasite burdens, suggesting that TLR2 is required for disease promotion. In RAW
macrophages,theinfectionwithL.amazonensispromotesthephosphorylationofPKRandtheactivationofthePKRpromoterandenhances
the synthesis of both PKR and of type 1-IFNs, and those events require TLR2 [33]. The levels of SOD1 expression are elevated in association
with PKR activation and IFNβ production, resulting in increased parasite replication [33]. L. donovani downmodulates TLR2 responses
in macrophages by inhibiting MAPp38 kinase, leading to IL10 production [34]. The dashed lines indicate that intermediate steps of the
pathways are either not identiﬁed or not represented in the ﬁgure.
TNF-α secretion and the leishmanicidal activity of those
macrophages [51]. A global analysis of gene expression in
IFN-γ-treated THP-1 macrophages infected with L. major
showed that genes related to TLR signaling are also diﬀer-
entially expressed upon infection [46], revealing how the
parasite could interfere with the capacity of the host cell to
respond via TLR-mediated routes. L. major can also induce
the expression of TLR2, TLR7, and TLR9 in polymorphic
nuclear cells (PMNs) from C57BL6 mice [52], evidencing
that infection provokes alterations in the levels of several
TLRs in multiple cells of the innate system.
Additional parasite molecules were implicated in TLR2
activation. The L. infantum protein related to the silent
information regulator 2 (SIR2) family leads to the pro-
liferation of activated B lymphocytes, causing increased
expression of major histocompatibility complex (MHC)
II and the costimulatory molecules CD40 and CD86, in
a TLR2-dependent fashion [53]. The maturation of DCs
induced by SIR2, accompanied by the secretion of IL12 and
TNF, was also dependent on TLR2, while the activation of
macrophages still took place in the absence of TLR2.
Other studies suggest that Leishmania downregulates
TLR2-mediated responses and attempted to dissect some
of the downstream molecular pathways involved therein.
The infection of human THP1-derived macrophages by L.
donovani in vitro suppresses TLR2 and TLR4-stimulated IL-
12 release, with an increase in IL-10 production, through
parasite-dependent contact [54]. Parasites were shown to
negatively modulate the TLR2-stimulated signaling pathway
by suppressing MAPKp38 phosphorylation and activating
extracellular regulated kinase (ERK)1/2 phosphorylation
[54]. It was also reported that L. donovani, L. mexicana,Journal of Parasitology Research 5
and L. major exploit the macrophage tyrosine phosphatase
SHP-1 to inactivate kinases involved in TLR signaling
[55]. The infection of bone-marrow-derived macrophages
in vitro leads to IRAK inactivation, impairing LPS-mediated
activation as well as macrophage function [55].
Studies using TLR2-deﬁcient mice revealed a somewhat
contrasting scenarium (Figure 1, right pannel). TLR2 was
necessary for the development of lesions in mice infected
with L. braziliensis [56]. While MyD88−/− mice developed
larger and prolonged lesions compared to those in control
mice, the lack of TLR2 resulted in enhanced DC activation
and increased IL-12 production after infection. L. brazilien-
sis-infected TLR2-deﬁcient DCs were more competent in
priming na¨ ıve CD4 T cells in vitro, correlating with increased
IFN-γ production in vivo and enhanced resistance to infec-
tion. More recently, it was reported that TLR2-deﬁcient
mice are also less susceptible to the infection with L.
amazonensis than the wild-type C57BL6 counterpart, as
evidenced by lower parasite burden and reduced recruitment
of inﬂammatory cells in the ﬁrst weeks of infection [57]. At
the same time, it was described that the activation of the
protein kinase PKR during the infection of macrophages by
L. amazonensis is crucial for parasite survival [58]. Finally,
The engagement of PKR and the subsequent production
of type-1 IFNs and of superoxide dismutase (SOD-1) were
necessary for eﬀective parasite growth and dependent on
TLR2, indicating that this TLR is required for the successful
infection of macrophages by L. amazonensis [47]. Those
ﬁndings suggest that TLR2 plays a role in facilitating the
establishment of the disease, depending on the Leishmania
species in question.
2.2. TLR4. Besides the direct activation of TLRs by parasite
molecules, the engagement of those receptors indirectly by
nonparasite ligands during phagocytosis could inﬂuence the
outcome of infection. Studies using TLR4−/−mice indicated
thatthisreceptorplaysaprotectiveroleinL.major infections
[48]. The authors observed diminished parasite load at the
skin lesions of infected mice at the initial stages of infection,
that is, 24h, and found increased parasite survival in host
cells from TLR4-deﬁcient mice, which correlated with a
higher activity of arginase [48] .T h es a m eg r o u ps u b s e -
quently showed that the lack of TLR4 results in increased
parasite growth during both the innate and adaptive phase
of the immune response and in delayed healing of the
cutaneous lesions [59]. However, TLR4 does not seem
importanttodeﬁnetherangeofchemokinesproducedinthe
skin or in the draining lymph nodes of mice infected with L.
major [60]. In agreement with a protective role for TLR4, it
was described that the lack of SLAM, a cell surface receptor
of macrophages that regulates TLR4-transduced signals,
increased the susceptibility of mice to L. major infections
[61]. Importantly, this phenotype was attributed to defective
macrophage function, suggesting that the activation of host
cell TLR4 contributes to the control of parasite growth in
vivo. The ﬁrst potential TLR4 ligand present in Leishmania
was described a few years ago in L. pifanoi amastigotes and
consists of a proteoglycolipid complex (P8) composed of a
cysteine and serine metalloprotease, host-derived ApoE, and
four glycolipids [62, 63]. Stimulation of macrophages with
P8oritsisolatedglycolipidsprovokedthesynthesisofarange
of proinﬂammatory cytokines, including IL1β and TNFα
and the responses to intact P8 were dependent on TLR4,
MD2, CD14, and MyD88 [62]( Figure 2, left). However,
the exact molecular entity serving as the TLR4 ligand in
P8 still remains to be determined. More recently, TLR4
was implicated in the mechanism underlying the inhibition
of IL-12 production in LPS-treated macrophages infected
with L. mexicana. Metacyclic promastigotes were found to
greatly increase the phosphorylation of the three major MAP
kinases,ERK,p38,andJNK,inamannerdependentonTLR4
but not on TLR2 [64]. Parasites prolonged the induction of
iNOS or COX-2 expression in LPS-stimulated macrophages,
enhanced PGE2 and NO production, and increased the
expression of arginase-1. The induction of iNOS, COX-2,
and arginase-1 were also dependent on TLR4, supporting
the hypothesis that this TLR plays an anti-inﬂammatory role
in macrophages during L. mexicana infections, ultimately
preventing IL-12 production.
On the other hand, the anti-leishmanial role of TLR4
mightbeexertedbymultipledownstreameﬀectormolecules.
For example, macrophages of the mouse strain SPRE/Ei,
which is resistant to LPS, have normal MyD88-mediated
signaling pathways but are defective in the production of
type-1 IFNs [65]. Those mice were found to be highly
susceptible to L. major, a feature that was attributed
to the poor induction of IFNβ-dependent genes. These
observations suggest that type-1 IFNs pose as eﬀectors
that, through a paracrine/autocrine loop, contribute to
parasite control downstream of TLR4 stimuli. The cross-talk
between TLR4 and additional receptors should also be taken
into consideration when viewing anti-leishmanial properties
attributed to this TLR. For example, in macrophages,
the stimulation of the glucocorticoid receptor by pro-
gesterone downmodulates TLR4-induced NO and IL-12
production and reduces the killing of L. donovani by
activated macrophages [66] Likewise, complement-derived
C5a negatively regulates TLR4-induced IL-12, IL-23, and IL-
27 in macrophages, leading to decreased Th1 responses in
vivo [67]. It was found that Th1- enhanced immunity in
C5a-receptor−/−mice confers protection against an L. major
challenge [67], exemplifying how other receptors of innate
immunitymightaﬀectsusceptibilitytoleishmaniainfections
through the modulation of TLR responses.
The engagement of TLRs during the interaction between
diﬀerent cells of the innate system can also dictate the fate of
parasites in infectedmacrophages. It was reported that apop-
totic neutrophils from C57B6 mice induce the production of
TNF-α by L. major-infected macrophages in vitro, leading
to parasite elimination [68]. Later on, the activation of
macrophage TLR4 by the neutrophil-derived serine protease,
neutrophil elastase (NE), was proposed as the underlying
mechanism leading to parasite death [69]( Figure 2,s c h e m e
c). More recently, the phagocytosis of apoptotic neutrophils
by bone-marrow-derived macrophages in a proinﬂamma-
tory context in vitro was found to induce a stable M2b
phenotype,renderingthosemacrophagesmorepermissiveto6 Journal of Parasitology Research
CR3
ROS
Phagocytosis M2b
Parasite replication 
Parasite killing
Macrophage
NE
NE
NE
NE NE NE NE complex
NE Neutrophil elastase
Amastigote
Promastigote
Apoptotic neutrophil
ISP2
IL-1β
CD14
MD2
TLR4
P8
L. pifanoi
L. major
CD14
MD2
TLR4
CD14
MD2
TLR4
CD14
MD2
TLR4
L. major
TNFα
IL-10 Parasite killing
TNFα
L. major
(a) During phagocytosis (b) Before phagocytosis (c) After phagocytosis
Figure 2:ModelfortheactivationofTLR4indiﬀerentsettingsofLeishmaniainfections.L.pifanoiamastigote-derivedP8glycolipidcomplex
stimulatesTLR4inmacrophagesinanMD2,CD14,andMyD88-dependentmanner,leadingtotheproductionofproinﬂammatorycytokines
(left panel) [46]. Microenvironments during the activation of TLR4 in macrophages of C57BL6 mice by neutrophil elastase (NE): in (a),
during the phagocytosis of L. major promastigotes, CR3, TLR4, and NE at the surface of macrophages increase parasite uptake but lead to
ROS production and to partial parasite elimination within 24h [47], the control of NE activity by parasite ISP2 prevents TLR4 activation
and protects parasite from intracellular killing [47, 48]; in (b), macrophages remove apoptotic neutrophils by phagocytosis and acquire a
M2b phenotype, leading to IL10 production and increased permissiveness to parasite growth; in (c), macrophages are infected by L. major
and subsequently interact with apoptotic neutrophils, resulting in the activation of TLR4 by NE and in the production of TNF that promotes
parasite killing.
the replication of L. major [70]. The induction of the M2b
phenotype, correlating with higher IL10 levels and a Th2-
type response, was dependent on TLR4 and NE activities,
suggesting that the engagement of TLR4 might be beneﬁcial
to the parasite at later stages of infection (Figure 2,s c h e m e
b). Indeed, rechallenge of those macrophages with LPS
promoted parasite growth and the treatment of C57B6 mice
with apoptotic neutrophils 3 days before infection increased
parasiteburdens,demonstratinghowTLR4-mediatedsignals
can contribute to create permissive niches for parasite
replication at later stages [58].
We have recently described that NE present at the
surface of murine macrophages can also activate TLR4
during the phagocytosis of L. major, without requirement
of neutrophils [71]. Wild-type L. major is able to control
NE activity, at least in part, through its endogenous protease
inhibitorstructurallysimilartobacterialecotins,namedISP2
(inhibitor of serine peptidases) [72]. Parasites lacking ISP2
promptly engage macrophage TLR4 due to uncontrolled
NE activity [71]( Figure 2, scheme a). Furthermore, we
found cooperativity between TLR4 and CD11b, a subunit
of the complement type 3 receptor (CR3), in facilitating
the uptake of L. major by macrophages. TLR4 activation
led to the production of ROS, provoking partial elimination
of intracellular parasites a few hours after internalization
[71]. We found that the cooperativity between CD11b and
TLR4 to enhance the phagocytosis of parasites was strictly
dependent on the activity of NE, setting another example of
how multiple components of innate immunity can act con-
certedly to improve the defense against invading parasites.
The ability of Leishmania to promote the cross-talk between
those receptors might exacerbate TLR4 responses in light of
the ﬁnding that optimal signaling through TLR4 requires
multiplecellsurfaceassociatedmoleculessuchasCD11band
HSP90[73].WeobservedthatearlyengagementofTLR4can
inﬂuence how macrophages respond to L. major in at least
twofronts:(i)ﬁrst,bypromotingenhancedphagocytosisand
early killing of promastigotes (i.e., 24hrs), and (ii) secondly,Journal of Parasitology Research 7
by restraining the subsequent growth of amastigotes in the
following 2–4 days. Those observations suggest that signals
mediated through TLR4 at the parasitophorous vacuole
could aﬀect the microenvironment surrounding the parasite,
controlling sustained intracellular growth.
Recently, a screen of TLR4 mutations in patients with
cutaneous leishmaniasis revealed that certain genotypes
were largely favoured in individuals with chronic or acute
disease,ascomparedtoasymptomaticdonorsornoninfected
individuals, leading to the proposal that TLR4 polymor-
phism may lead to increased susceptibility or severity of the
disease [74]. Although the consequences of TLR activation
i nm a c r o p h a g e sa sar e s u l to fLeishmania infections are
being widely investigated, we are still lacking information
on how TLRs might aﬀect the interaction of the parasites
with neutrophils. The mobilization of TLRs in neutrophils,
in particular that of TLR4, is known to induce a wide
range of responses. Of interest, IRAK4 is crucial for the
exocytosis of neutrophil secretory granules induced by TLR4
[75]. In view of the ﬁndings that NE aﬀects the outcome of
parasite growth in macrophages [69–71], the stimulation of
TLR4 in neutrophils could regulate the levels of secreted NE,
inﬂuencing parasite burden in macrophages.
2.3. TLR9 and TLR3. Studies aiming at improving the
therapy for L. major infections using recombinant IL-
18 pointed to a potential involvement of the CpG-TLR9
pathway in the protective antiparasite response. While
promoting rIL18 expression in infected mice through gene
gun delivery, the authors observed a synergistic role of the
plasmid vector with rIL18, which was dependent of CpG
motifs [76]. The induction of proinﬂammatory cytokines,
in particular of IL-12, by antigen-presenting cells was found
to be dependent on TLR9 activation by CpG, indicating
that TLR9 stimulation could lead to protective immunity
againsttheparasite.InattemptingtodeﬁnewhichTLRswere
involved in the increased susceptibility of MyD88-deﬁcient
mice to Leishmania infections, Liese and coworkers showed
that TLR9 was required to induce IL-12 in bone-marrow-
derivedDCsbyeitherL.major oritsDNA[77].Furthermore,
they observed that TLR9−/− m i c ee x h i b i t e dm o r es e v e r es k i n
lesions and higher parasite burdens as compared to C57B6
controls, coupled to a transient increase in IL-4, IL-13, and
arginase.EventhoughtherewasanincreaseinTh2cytokines,
they did not observe alterations in the levels of IFNγ in the
draining lymph node, concluding that deﬁciency in TLR9
does not inﬂuence the quality of the Th1 response [77].
The same group reported that plasmacytoid DCs responded
to L. infantum by secreting IFNs α and β and IL-12 in a
TLR9-dependent manner and that NK-induced cytotoxicity
was abolished in TLR9−/−mice [78]. Those results were the
ﬁrst to link TLR9, IL-12, and DCs to the activation of NK
cells during visceral leishmaniasis. The protective role of NK
cells in murine leishmaniasis is now proven to be strictly
dependent on IL-12 secreted by myeloid DCs in response to
Leishmania via TLR9 (reviewed in [14]).
The involvement of TLR9 in controlling L. major infec-
tion was further investigated in the following studies. Lesion
progression and parasite burden were higher in TLR9−/−
mice as compared to C57BL/6 controls, which was concomi-
tant with a transient inhibition of a Th1 response [79]. The
authors showed that the activation of bone-marrow-derived
DCs, or of DCs isolated from the spleen, by L. major or by
parasite DNA, followed by IFN-γ production by CD4 T cells,
was abolished by treatment with DNAse or by alkalinization
of endosomal compartments with chloroquine, supporting a
role for TLR9 in DC activation by the parasite [79]( Figure 3,
left panel). Those ﬁndings caused some controversy as to the
impact of TLR9 deﬁciency in attenuating the Th1 response
[80]. Since in both studies there were delays in the healing
of skin lesions in TLR9−/− mice, it is feasible that the
Th1 response is at least partially compromised in those
mice.
The recognition of Leishmania by TLR3 in endosomal
compartments was brought up a few years ago. Experiments
using RNA interference provided evidence that in IFN-γ
primed macrophages, TLR3 is required for the production
of NO and TNF-α induced by infection with L. donovani,
besides contributing to parasite phagocytosis [81]( Figure 3,
right panel). Since Leishmania does not contain double-
stranded RNA, the standard ligand for TLR3, the origin
of the stimulatory factor of TLR3 remained an open
question. More recently, an elegant work from Ives and
coworkers shed light on this matter, providing evidence
that RNA from viruses present in L. guyanensis serve as a
source of TLR agonists, promoting inﬂammatory cytokines
and chemokines [82]( Figure 3, right panel). The elevated
cytokine production was dependent on the TLR3-TRIF
pathway, and augmented via MyD88-transduced signals.
Intriguingly,thoseresponsesrenderedmicemoresusceptible
to infection, as observed by increased swelling and parasite
burden, together with more pronounced metastasis. Those
ﬁndings add to the growing list of examples where the sub-
version of TLR responses by Leishmania serves to promote
infection instead of playing a protective role.
Additional factors can further inﬂuence TLR activation
indirectly, aﬀecting the outcome of adaptive immunity.
For example, it was found that dyslipidemia inhibits TLR-
induced production of IL-12, IL-6, and TNF-α,a sw e l la s
upregulation of costimulatory molecules by CD8α− DCs, in
vivo, leading to impaired Th1 and enhanced Th2 responses.
Such dysfunction compromised host resistance to L. major,
revealingthatadyslipidemicmicroenvironmentcaninterfere
with DC responses to Leishmania through TLRs [83].
2.4. TLRs Stimulation in Vaccination and Immunotherapy.
The use of TLR activators as adjuvants in formulations to
improve the eﬃcacy of experimental vaccination against
Leishmania has also been largely explored. Even before
the knowledge that TLR stimulation could play a role in
the defense against Leishmania, CpG oligodeoxynucleotides
(ODNs) were tested as an adjuvant in the immunization
of mice with L. major-soluble antigen aiming at inducing
a protective Th1 response, leading to improved survival
[84]. This observation supported the proposal that TLR
agonists could serve as cost-eﬀective alternatives in vaccine8 Journal of Parasitology Research
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Figure 3: Proposed models for the activation of intracellular TLR9 and TLR3 by Leishmania. TLR9 of plasmocytoid DCs (pDCs) can be
activatedbyputativeTLR9ligandssecretedbyL.infantumpromastigotesandtakenupbyendocytosisorinendosomalcompartments.TLR9
in myeloid DCs (mDCs) can be activated by L. infantum DNA after parasite phagocytosis and destruction in the endosomal compartment,
leading to the activation of NK cells and protective Th1 responses [4, 63, 64]. TLR3 is required for the production of TNF, NO and the
phagocytosis of L. donovani by macrophages, suggesting a protective role for infection [67]. Intracellular TLR3 is activated in a TRIF-
dependent pathway in macrophages infected with metastatic L. guyanensis, by double-stranded RNA from the Leishmania virus LRV1 [68].
This leads to the production of proinﬂammatory cytokines and chemokines, as well as type1-IFNs. Despite the inﬂammatory response,
TLR3isrequiredfortheeﬀectivedevelopmentoffootpadswelling,forsigniﬁcantparasiteburdenanditsdisseminationininfectedhamsters,
suggesting that TLR3 activation facilitates disease pathology by parasites of the Leishmania Viannia subgenus.
formulations against leishmaniasis. Along those lines, the
formulation of multisubunit recombinant vaccines with the
TLR4 agonist, monophosphoryl lipid A, elicited protective
immunity against L. major challenge in Balb/c mice, an
approach that could serve as an alternative to the use of
recombinant IL12 [85]. An analogue of lipid A was subse-
quently used as a TLR4 agonist in experimental vaccination
with L. amazonensis antigens and was proven beneﬁcial for
both immunoprophylaxis and immunotherapy, associated
mainly with increased levels of IL12 and IFNγ [86]. CpG
(ODN) were throughoutly tested as adjuvants in experimen-
tal vaccinations to induce protective responses toL. donovani
[87, 88], or to L. major in Balb/c mice, when coencapsulated
with antigens in liposomes [89]. CpG also protected Balb/c
mice immunized with ribosomal proteins against a second
challenge with L. major, being eﬀective in providing long-
term immunity [90, 91]. Finally, Cpg ODN improved the
clinical outcome of immunized rhesus macaques infected
with L. major, supporting the hypothesis that TLR9 stim-
ulation might improve the eﬃcacy of vaccination against
cutaneous leishmaniasis [92]. Using a combined approach
of costimulation of diﬀerent TLRs, the immunogenicity of
recombinant antigens from L. donovani (iron superoxide
dismutase B1 and peroxidoxin 4) was greatly improved by
immunization in conjunction with TLR9 or TLR4 agonists,
resulting in a Th1-type response in Balb/c mice [93]. The
use of ligands for TLR7 and/or TLR8 (imiquimod and the
relatedR848compound)intheimmunizationofBalb/cmice
with crude L. major antigen induced a Th1 response and was
protective against subsequent challenges [94].
More recently, the formulation of a deﬁned polyprotein
anti-LeishmaniavaccinecandidateinconjunctionwithTLR4
or TLR9 agonists was evaluated as an immunotherapeutical
treatment in a mouse model of cutaneous leishmaniasis
[95]. A strong eﬀective T cell response was observed during
disease, followed by cured lesions and reduced parasite
burden upon immunization with the combination of both
agonists, suggesting that TLR synergy may serve as a tool
for the treatment of parasite infection. TLR2 stimulation was
also proposed as an alternative to revert the loss of CD8
function in patients with diﬀuse cutaneous leishmaniasis
[96]. It was found that, in patients infected with L. mexicanaJournal of Parasitology Research 9
who develop diﬀuse lesions, the reduced cytotoxicity and
proliferation of CD8 cells was typical of cellular exhaus-
tion and could be restored in vitro by stimulation with
TLR2 agonists, including Leishmania LPG [96]. The design
of CD8 activators based on TLR2 activation could be
beneﬁcial in reverting the observed in chronic patients
with diﬀuse lesions. More recently, a more sophisticated
vaccination approach was attempted in order to promote
protective responses against L. panamensis in a murine
model of chronic disease [97]. The strategy of prime-
boost, consisting of the priming using a single antigen and
heterologous DNA, was combined with the addition of a
TLR2/1 agonist (PAM3CSK4) as an adjuvant, leading to an
eﬀective protection against L. pananemensis infections [97].
Furthermore, they provided evidence that TLR2 stimulation
during priming is essential for the elevation of CD4 and CD8
memory T cell responses and reduction of IL-13 and IL-10
levels, which were required for protection. Those ﬁndings
were a great step forward in the design of simple and
cost-eﬀective vaccines against Leishmania (Viannia)s p e c i e s
that are refractory to commonly used strategies to other
Leishmania species. It also oﬀers an alternative for DNA-
based vaccination schemes in cases where the CD8 T cell
activation is crucial.
3. Concluding Remarks
The activation of several members of the TLR family of
receptors is observed during the infections of isolated cells
or in experimental infections of animals with diﬀerent
Leishmania species. The consequences of such activation are
complex and depend on the nature of the TLR, the cell
type, the parasite species, and the timing in which those
events occur. Although studies using TLR-deﬁcient animals
oﬀered the initial picture of how those receptors can act
in the protection or promotion of disease, the underlying
molecular mechanisms are still obscure. In particular, it is
indispensable to identify the parasite factors that contribute
to TLR activation and/or negatively regulate their responses
in the individual cell types and to evaluate to what extent
TLRactivationineachofthosecellscontributestopathology.
While most of the earlier studies focused on the requirement
of TLRs for cytokine synthesis and for the development
of adaptive immunity, the studies on if and how those
receptors contribute to the biogenesis of the parasitophorous
vacuole and to the control of parasite intracellular growth
are still largely missing. TLR activation has emerged as a
promising alternative to improve the eﬃcacy of vaccination
with parasite antigens and may also act synergistically with
other components during immunotherapy. However, a more
detailed study of the consequences of such strategies must
be addressed before the combined activation of TLRs can be
explored in the future in the treatment of patients with more
severe and diﬀuse lesions.
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